Lexington, MA – Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology’s (ASN) Kidney Week 2011. The annual meeting will be held November 8-13, 2011 in Philadelphia, PA. Full abstracts can be viewed online at http://www.asn-online.org/education_and_meetings/kidneyweek/archives/.

The schedule and details for the CTP-499 abstracts and poster presentations at ASN are as follows:

“Design and Rationale for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of CTP-499 in Patients with Diabetic Nephropathy; Publication in JASN Abstract Supplement; PUB195.

About CTP-499

CTP-499 is an analog of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX), an active metabolite of pentoxifylline. CTP-499, a potential first-in-class treatment for diabetic nephropathy, possesses a pleiotropic mechanism of action with anti-inflammatory, anti-oxidant and anti-fibrotic properties that are different from the current standard-of-care, including angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). CTP-499 was developed using Concert’s DCE Platform™ to provide a new chemical entity with an improved pharmacokinetic profile.

Concert has completed two healthy volunteer, Phase 1 studies, specifically an assessment of CTP-499 controlled release formulations and a single ascending dose study. Concert intends to commence a Phase 2 clinical trial evaluating CTP-499 in patients with diabetic nephropathy in the first half of 2012.

About Diabetic Nephropathy

Diabetic nephropathy is a common consequence of diabetes and is the leading cause of chronic kidney disease (CKD) and need for dialysis in the US. Current standard of care for CKD is treatment with blood pressure lowering agents that affect the renin-angiotensin system, including ACEi and ARBs. Despite the availability of these treatments, many patients progress to renal failure. According to the US Renal Data System, the number of end-stage renal failure patients in the US doubled between 1994 and 2008. There is a critical need for a new agent with a novel mechanism that delays or prevents the decline of kidney function and eventual need for dialysis.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The Company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.